Jafron Biomedical Co., Ltd. (“Jafron”), an international company in the hemoadsorption industry, recently announced that Dr. Jin has joined Jafron as Vice President who will spearhead Jafron's international growth through marketing optimization, cooperation, and global investment.   

Dr. Jin is an experienced professional and global business leader with more than 25 years of experiences in the healthcare industries, including 8 years in the blood purification field (Acute Therapies and Renal Care). Prior to join Jafron, with increasing responsibilities, Dr. Jin served in Bayer Healthcare, BD and Baxter respectively. As a PhD of Biochemistry and Biophysics graduated from Oregon State University, Dr. Jin has a deep understanding of blood purification, critical care medicine, and drug infusion. Her new role also means Jafron will strengthen its efforts to explore global markets.

Jafron's innovative hemoperfusion therapies are currently available in more than 80 countries and regions worldwide, and in the first half of 2021, its global market revenue reached the year-on-year increase of more than 200%. In addition, in June 2021, Jafron established a MOST (Multi-Organ Support Therapy) Advisory Board composed of 6 world-class clinical researchers and intensive care experts. 

In the coming years, Jafron’s increasing influence in world’s hemoadsorption industry will be paired with a commitment to innovation and knowledge sharing in the healthcare community and it will provide medical researchers and physicians worldwide with more efficient therapies for meeting the rapid development of the blood purification industry.